The UK and US have concluded a landmark trade agreement that will preserve zero duties on British medicine products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these key exports will be held at zero for a period of three years.
This development comes after earlier warnings to hike import taxes on branded drug products, with figures discussed reaching double the cost.
"This agreement between the UK reinforces the global environment for innovative medicines and establishes long-overdue fairness to transatlantic medicine commerce," a release noted.
Commercial Importance
Medicines constitute one of the UK's biggest exports to the US, which is by far the primary buyer for large British pharmaceutical firms.
Statistics indicate that in the one-year period prior to the third quarter, the UK exported medicines worth £11.1bn to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This agreement safeguards work, stimulates funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The pact includes several key pledges from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
This agreement comes amid a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were heightened by arguments that US customers were charged significantly more for the equivalent treatments than patients in the other developed nations.
In recent months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a share of its total funding over the past decade.
